Dexamethasone implant authorized for DME

Article

The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.

The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.

“This is good news because [dexamethasone] therapy can potentially improve the quality of life for patients with DME by resolving their macular oedema, improving their visual function for daily activities such as reading and driving, and by reducing the burden of very frequent hospital visits with just four to five injections required over 3 years,” said Professor Yit Yang, consultant ophthalmic surgeon from Wolverhampton Eye Infirmary and Birmingham and Midland Eye Centre.

The safety and efficacy of the implant in the management of patients with DME was assessed in the MEAD clinical trials program, two 3-year, multicentre, double-masked, randomized controlled phase III studies of more than 1,000 patients who received either 350 mcg or 700 mcg of the drug or sham (simulated) injections. The results showed:

  • The percentage of patients with a 15 or more letter gain was significantly greater in those treated with dexemethasone than sham at 3 years.
  • Meaningful treatment benefit was observed with a mean of 4 to 5 injections over 3 years.
  • Rapid onset of treatment benefit was observed after the first and repeated dexamethasone injections.
  • Treatment with 700 mcg of dexamethasone was generally well-tolerated with manageable adverse effects. The drug demonstrated good systemic safety. Common adverse events included elevated IOP and cataract, consistent with previous observations.

The implant is already available in the UK as a treatment licensed for macular oedema in patients with retinal vein occlusion and for inflammation of the posterior segment of the eye characterized as non-infectious uveitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.